Results

Total Results: 1,426 records

Showing results for "stage".

  1. S123 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/s123.pdf
    October 01, 2007 - effect.29–31 No study contained only stage II patients, and in the study with the most stage II patients … affected the surgery choices for both stage I and stage II patients, whereas the local area BCSI rate … affected only the surgery choices for stage II patients and did not affect the surgery choices for stage … linear probability model and the IV estimates using combined stage I and stage II patients are consistently … Patient Groups Per Instrument ESBC Patients All (N � 6185) Stage I (N � 3280) Stage II (N � 2905
  2. effectivehealthcare.ahrq.gov/sites/default/files/related_files/colon-cancer-gene-profiling_disposition-comments.pdf
    December 14, 2012 - Technical Brief Disposition of Comments Report for Gene Expression Profiling for Predicting Outcomes in Stage … Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer. Technical Brief. … (and stage subgroups) separates patients into prognostic subsets. … Nitsche reported that ColoPrint identified most stage II patients (73%) as low risk. … Tabernero reported “ColoPrint classifies two-thirds of the stage II patients as Low Risk.
  3. effectivehealthcare.ahrq.gov/products/colorectal-cancer/abstract
    April 14, 2010 - Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age … Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage … Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage … of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage
  4. effectivehealthcare.ahrq.gov/sites/default/files/related_files/ocd-draft-report-kq2-appendix.xlsx
    January 01, 2023 - ES 95% CI SE P-Value Favors Strength 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks (post-treatment … Gender NR B 0.35  -1.79 to 2.49 0.75 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage … 0.86 0.04 7-11 Strength unclear (Continuous predictors; P<0.05) 25721185 Torp 2015 GPA NordLOTS, stage … ≥22 vs <22 B 0.06 -0.01 to 0.13 0.83 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage … Yes vs no B 1.18 -1.33 to 3.69 0.356 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage
  5. effectivehealthcare.ahrq.gov/products/renal-disease-therapies
    March 31, 2011 - Comparative Effectiveness of Antihypertensive Therapies on Cardiovascular Disease Outcomes In End-Stage … Comparative Effectiveness of Antihypertensive Therapies on Cardiovascular Disease Outcomes In End-Stage
  6. effectivehealthcare.ahrq.gov/products/renal-disease-iron
    January 24, 2012 - Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage Renal … Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage
  7. effectivehealthcare.ahrq.gov/products/renal-disease-anemia
    March 31, 2011 - Comparative Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage … Comparative Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage
  8. effectivehealthcare.ahrq.gov/products/chronic-kidney-disease-anemia
    January 14, 2013 - Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future … Review Archived Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage
  9. effectivehealthcare.ahrq.gov/products/kidney-disease-medicine/research-protocol
    July 28, 2010 - Within this framework, K/DOQI then classified CKD into five stages as follows: Stage 1: Kidney damage … with GFR >90 mL/min/1.73 m 2 Stage 2: Kidney damage with GFR 60-89 mL/min/1.73 m 2 Stage 3: GFR … 30-59 mL/min/1.73 m 2 Stage 4: GFR 15-29 mL/min/1.73 m 2 Stage 5: GFR <15 mL/min/1.73 m 2 or kidney … (2) Albuminuria stages should be added within each GFR stage (urinary ACR <30 mg/g, 30-299 mg/g, or … stage 2 CKD, 7.7% (15.5 million) in stage 3 CKD, and 0.4% (0.7 million) in stage 4 CKD. 3 U.S. prevalence
  10. effectivehealthcare.ahrq.gov/sites/default/files/pdf/kidney-disease-medicine_research-protocol.pdf
    November 01, 2010 - 2: Kidney damage with GFR 60-89 mL/min/1.73 m2 • Stage 3: GFR 30-59 mL/min/1.73 m2 • Stage 4: GFR … (2) Albuminuria stages should be added within each GFR stage (urinary ACR <30 mg/g, 30-299 mg/g … Epidemiology of CKD Based on the K/DOQI CKD definition and stage classification, and utilizing a … Of the population,1.8% (3.6 million) individuals were classified in stage 1 CKD, 3.2% (6.5 million) … in stage 2 CKD, 7.7% (15.5 million) in stage 3 CKD, and 0.4% (0.7 million) in stage 4 CKD.3 U.S.
  11. effectivehealthcare.ahrq.gov/sites/default/files/related_files/lung-cancer-nonsurgical-therapies_executive.pdf
    June 01, 2013 - 1 Comparative Effectiveness Review Number 112 Local Nonsurgical Therapies for Stage I and Symptomatic … I, stage II, and selected stage III tumors) • Potentially operable or inoperable locally (T3–T4) … Several radiotherapy modalities have been used to treat patients with stage I NSCLC. … Surgery is the standard of care for eligible patients with stage I NSCLC. … The treatment of early-stage disease. Semin Radiat Oncol. 2010 Jul;20(3):178-85.
  12. effectivehealthcare.ahrq.gov/sites/default/files/related_files/lung-cancer-nonsurgical-therapies_disposition-comments.pdf
    June 12, 2013 - Disposition of Comments for Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell … The CER is about local, nonsurgical interventions for stage I NSCLC. … There is a lack of analysis for RFA of medically inoperable stage I NSCLC. … Stereotactic body radiation therapy for inoperable early stage lung cancer. … , not “local therapies for stage I” lung cancer as stated.
  13. effectivehealthcare.ahrq.gov/products/colorectal-cancer-staging/research
    September 10, 2014 - Treatment options for colorectal cancer differ depending on the clinical stage of disease at diagnosis … cancer T (tumor) staging, ERUS is more accurate than CT; ERUS is less likely than CT to incorrectly stage … MRI was less likely to overstage preoperative rectal cancer N stage than CT (OR = 0.498; 95% CI, 0.308
  14. effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-cancer-staging_disposition-comments.pdf
    November 20, 2014 - This is an understatement since the standard of care for stage II and III rectal cancer is neoadjuvant … Table A: The table shows specificity of T1 stage as 75.8. … For preoperative rectal cancer T (tumor) staging, ERUS is less likely than CT to incorrectly stage ( … Specifically, most of the analyses on T-stage did not distinguish the strengths of ultrasound vs MRI … late T-stage extent.
  15. effectivehealthcare.ahrq.gov/health-topics/anemia-0
    April 25, 2013 - Archived June 16, 2010 Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage
  16. effectivehealthcare.ahrq.gov/sites/default/files/Evidence%20Summary_2.pdf
    May 01, 2020 - of labor (low SOE) or duration of the second stage of labor (low SOE). … The natural history of the normal first stage of labor. … Effects of LI4 acupressure on labor pain in the first stage of labor. … Upright position during the first stage of labor: a randomised controlled trial. … Maternal positions and mobility during first stage labour.
  17. effectivehealthcare.ahrq.gov/products/colorectal-cancer-staging/research-protocol
    May 21, 2013 - However, stage is the key determinant of the management strategy. … that is compared against the stage established by the reference standard. … Stage reclassification or clinical decision impact . … Stage reclassification . … The change in stage of the cancer after imaging, compared with the stage determined based on information
  18. effectivehealthcare.ahrq.gov/sites/default/files/data-points_1_diabetic-foot-ulcers_data_02-2011.pdf
    January 01, 2011 - Diabetes Diabetes Rate in Enrolled Population Total All 2006 32.8 8.7 26.4% Age Disabled/end stage … American Indian/Alaska Native 2006 0.1 0.1 36.0% Total All 2007 32.3 8.8 27.3% Age Disabled/end stage … American Indian/Alaska Native 2007 0.2 0.1 37.3% Total All 2008 31.9 8.9 27.9% Age Disabled/end stage … Beneficiaries With Diabetes and Without PAD Total All 2006 8.1% 19.2% 5.0% Age Disabled/end stage … Beneficiaries With Diabetes and Without PAD Total All 2006 1.8% 6.5% 0.6% Age Disabled/end stage
  19. effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-report-testing-machine-learning-tool-chronic-pain.pdf
    November 01, 2020 - (Stage 3). … on monthly update searches (Stage 3). … Stage 2: Test Machine Learning Classifier on Optimized Searches In Stage 2, we aimed to develop machine … Background Methods Stage 1: Develop Optimized Search Strategies Stage 2: Test Machine Learning Classifier … Search Strategies Stage 2: Test Machine Learning Classifier on Optimized Searches Stage 3: Test Machine
  20. effectivehealthcare.ahrq.gov/sites/default/files/data-points_2_diabetic-foot-ulcers_data_02-2011.pdf
    January 01, 2011 - Enrolled Beneficiaries With Diabetes and Without PAD Total All 2006 6.0% 13.5% 4.0% Age Disabled/end stage … Beneficiaries With Diabetes and Without PAD Total All 2006 0.5% 2.1% 0.053% Age Disabled/end stage … Indian/Alaska Native 2006 1.0% 5.6% 0.135% Total All 2007 0.5% 1.9% 0.055% Age Disabled/end stage … Indian/Alaska Native 2007 0.8% 4.7% 0.131% Total All 2008 0.4% 1.8% 0.058% Age Disabled/end stage … Enrolled Diabetic Population Q1 Q2 Q3 Q4 Total All 2006 1.76% 1.81% 1.68% 1.47% Age Disabled/end stage

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: